Result card

  • EFF3a: Are IVIG effective in reducing overall mortality in patients with Mild Cognitive Impairment when compared to placebo?
  • EFF3b: Are IVIG effective in reducing overall mortality in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors? Jump to
  • EFF3c: Are IVIG effective in reducing overall mortality in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine? Jump to
English

Are IVIG effective in reducing overall mortality in patients with Mild Cognitive Impairment when compared to placebo?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with MCI.

Important
Completely
Vignatelli L et al. Result Card EFF3a In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in reducing overall mortality in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with mild-to-moderate AD.

Important
Completely
Vignatelli L et al. Result Card EFF3b In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in reducing overall mortality in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with moderate-to-severe AD.

Important
Completely
Vignatelli L et al. Result Card EFF3c In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References